Dave Muoio
The nearly 20-year-old brand started as an online hub for providers, but now hosts consumer-facing resources and in-person health clinics.
The company's lead offering for employer customers has so far reached more than 250,000 users.
The study, backed by the digital therapeutics company, measured the change in clinical encounter frequency among opioid use disorder patients who were also prescribed buprenorphine.
The tool was "100% accurate" when spotting cases among asymptomatic individuals, the researchers wrote, and could be deployed as a low-cost prescreener to support diagnostic testing efforts.
Outcomes from the randomized controlled trial were presented today at a virtual conference. The company and its research partners say this study differs from others due to its size and length.
Also: Digital therapeutics company Palo Alto Health Sciences reports $9.1 million; Adherium gains new support from investment firm Viburnum.
The fitness apparel brand said it will be throwing all its weight behind the MapMyFitness platform in an effort to better focus its digital strategy.
Newly published data from Scripps' DETECT study included data from 30,529 device owners, although only 333 of those who were symptomatic also provided their COVID-19 testing results.
Also: Vocalis Health and Mayo Clinic seek new pulmonary hypertension biomarkers; Sensyne Health and Microsoft's strategic partnership focuses on clinical AI co-development.
While the virtual care company maintains its momentum through the pandemic and Livongo merger, it also reported higher-than-expected losses during the quarter.